Core Insights - Amplia Therapeutics Limited presented interim data from the ACCENT trial for metastatic pancreatic cancer at the ASCO GI symposium, showcasing the efficacy of narmafotinib in combination with standard chemotherapy [1][3] Group 1: Clinical Trial Data - The ACCENT trial is assessing narmafotinib, a FAK inhibitor, in combination with gemcitabine and Abraxane for advanced pancreatic cancer patients [1][5] - Updated progression-free survival (PFS) for the narmafotinib combination is reported at 7.7 months, compared to 5.5 months for gemcitabine and Abraxane alone [6] - The overall response rate (ORR) for the narmafotinib combination is 35%, increasing to 42% when including unconfirmed responses [6][7] - The trial has achieved a confirmed response rate of 35%, superior to the 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone [7] Group 2: Company Overview - Amplia Therapeutics is focused on developing a pipeline of FAK inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer [4][5] - Narmafotinib (AMP945) is highlighted as a best-in-class FAK inhibitor, showing promising preclinical data and currently undergoing clinical trials [5][6] - The company is positioned among leading biotechnology firms, emphasizing its progress in developing narmafotinib for pancreatic cancer [3]

Core Insights - Amplia Therapeutics Limited is set to present updated data from the ACCENT trial at the ASCO Gastrointestinal Cancers Symposium, focusing on the combination of Narmafotinib with gemcitabine and nab-paclitaxel for metastatic pancreatic cancer [1][2] Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in Focal Adhesion Kinase (FAK) inhibitors aimed at treating cancer and fibrosis, with a focus on fibrotic cancers such as pancreatic and ovarian cancer [2] - FAK is recognized as a significant target in cancer treatment and is also involved in chronic diseases like idiopathic pulmonary fibrosis (IPF) [2] Drug Information - Narmafotinib (AMP945) is a potent and selective FAK inhibitor, currently in clinical trials, showing promising results in preclinical studies [3] - The ACCENT trial has achieved a confirmed response rate of 35%, surpassing the 23% response rate from the benchmark MPACT study for gemcitabine and Abraxane alone, with an interim median progression-free survival (PFS) of 7.6 months [3] - A second trial, AMPLICITY, is underway, investigating the combination of Narmafotinib with FOLFIRINOX in advanced pancreatic cancer patients [3]

Core Insights - Amplia Therapeutics Limited has reported an additional confirmed partial response in the ongoing ACCENT trial for metastatic pancreatic cancer, indicating progress in their clinical research [1][6] - The confirmed objective response rate (ORR) has reached 35% (19 out of 55 patients), which is significantly higher than the 23% ORR observed in the benchmark MPACT trial for gemcitabine and nab-paclitaxel alone [2][5] Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors targeting cancer and fibrosis, particularly in fibrotic cancers like pancreatic and ovarian cancer [4] - The company is advancing its lead candidate, narmafotinib, which is a potent and selective FAK inhibitor, currently being tested in the ACCENT trial in combination with gemcitabine and Abraxane for advanced pancreatic cancer [5] Clinical Trial Details - The ACCENT trial has achieved its primary endpoint with a confirmed response rate of 35%, surpassing the benchmark of 23% from the MPACT study [5] - An interim median progression-free survival (PFS) of 7.6 months has also been reported in the trial [5] - A second trial, AMPLICITY, is underway, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients [5]

MELBOURNE, Vic, Australia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (OTCQB:INNMF ASX:ATX), based in Melbourne, Australia and focused on developing new therapies for hard to treat cancers, today announced that Dr Chris Burns, CEO and Managing Director, will present live at Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on December 11th. DATE: December 11th TIME: 3:00 PM ETLINK: REGISTER HEREAvailable for 1x1 meetings: December 11, 15 and 16, after 3pm ET. ...

Core Viewpoint - Amplia Therapeutics Limited has received a key patent grant for narmafotinib, enhancing its intellectual property protection and extending it to at least 2040 in several jurisdictions [1][2][5]. Group 1: Patent and Intellectual Property - The US Patent and Trademark Office has granted a patent for a specific form of narmafotinib, which is crucial for the company's clinical development [1][2]. - The patent has also been granted in significant markets including Europe, Japan, India, Korea, and Australia, with ongoing reviews in other regions [2]. Group 2: Product Development - Narmafotinib (AMP945) is a potent FAK inhibitor targeting pancreatic cancer, showing promising results in preclinical studies [4]. - The drug is currently in the ACCENT clinical trial, demonstrating a confirmed response rate of 33%, which is higher than the 23% benchmark from the MPACT study [4]. - An interim median progression-free survival (PFS) of 7.6 months has been reported in the ACCENT trial [4]. - A second trial, AMPLICITY, is underway, investigating narmafotinib in combination with FOLFIRINOX for advanced pancreatic cancer patients [4]. Group 3: Company Overview - Amplia Therapeutics is focused on developing FAK inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers like pancreatic and ovarian cancer [3].